No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
XORTX Therapeutics Names Michael Bumby as CFO; U.S.-listed Shares Down 4%
Correction: -- XORTX Therapeutics Brief: Naming Dr. Michael Bumby, a Biotech/pharma Industry Veteran, as Its Chief Financial Officer Replacing James Fairbairn
XORTX Therapeutics Brief: Naming Dr. Michael Bumby, a Biotech/pharma Industry Veteran, as Its Chief Financial Officer Replacing James Fairbairn
XORTX Strengthens Executive Team
XORTX Therapeutics Unveils New Kidney Disease Discoveries
XORTX Announces Presentation at the Rare and Genetic Disease Summit